Pancancer Analysis of the Prognostic and Immunological Role of FANCD2: a Potential Target for Carcinogenesis and Survival

Overview

Journal BMC Med Genomics

Publisher Biomed Central

Specialty Genetics

Date 2024 Mar 5

PMID 38443946

Authors

Zedan Zhao

Ruyu Wang

Ruixue Wang

Jialing Song

Fengjun Ma

Huafeng Pan

Cuiyun Gao

Deqiang Wang

Xuemei Chen

Xiangzhen Fan

Affiliations

Soon will be listed here.

Abstract

Recent evidence has shed light on the significant role of FANCD2 in cancer initiation, development, and progression. However, a comprehensive pan-cancer analysis of FANCD2 has been lacking. In this study, we have conducted a thorough investigation into the expression profiles and prognostic significance of FANCD2, as well as its correlation with clinicopathological parameters and immune cell infiltration, using advanced bioinformatic techniques. The results demonstrate that FANCD2 is significantly upregulated in various common cancers and is associated with prognosis. Notably, higher expression levels of FANCD2 are linked to poor overall survival, as indicated by Cox regression and Kaplan-Meier analyses. Additionally, we have observed a decrease in the methylation of FANCD2 DNA in some cancers, and this decrease is inversely correlated with FANCD2 expression. Genetic alterations in FANCD2 predominantly manifest as mutations, which are associated with overall survival, disease-specific survival, disease-free survival, and progression-free survival in certain tumor types. Moreover, FANCD2 exhibits a strong correlation with infiltrating cell levels, immune checkpoint genes, tumor mutation burden (TMB), and microsatellite instability (MSI). Enrichment analysis further highlights the potential impact of FANCD2 on Fanconi anemia (FA) pathway and cell cycle regulation. Through this comprehensive pan-cancer analysis, we have gained a deeper understanding of the functions of FANCD2 in oncogenesis and metastasis across different types of cancer.

Citing Articles

Pancreatic Neuroendocrine Tumor: The Case Report of a Patient with Germline Mutation and Tumor Analysis Using Single-Cell RNA Sequencing.

Avsievich E, Salimgereeva D, Maluchenko A, Antysheva Z, Voloshin M, Feidorov I J Clin Med. 2025; 13(24.

PMID: 39768544 PMC: 11728285. DOI: 10.3390/jcm13247621.

Clinical Validation of the Somatic FANCD2 Mutation (c.2022-5C>T) as a Novel Molecular Biomarker for Early Disease Progression in Chronic Myeloid Leukemia: A Case-Control Study.

Alanazi N, Siyal A, Basit S, Shammas M, Al-Mukhaylid S, Aleem A Hematol Rep. 2024; 16(3):465-478.

PMID: 39051418 PMC: 11270283. DOI: 10.3390/hematolrep16030045.

RNA-binding protein transcripts as potential biomarkers for detecting Primary Sclerosing Cholangitis and for predicting its progression to Cholangiocarcinoma.

Ala U, Fagoonee S Front Mol Biosci. 2024; 11:1388294.

PMID: 38903178 PMC: 11187294. DOI: 10.3389/fmolb.2024.1388294.

Recent Advancements in Research on DNA Methylation and Testicular Germ Cell Tumors: Unveiling the Intricate Relationship.

Nicu A, Ionel I, Stoica I, Burlibasa L, Jinga V Biomedicines. 2024; 12(5).

PMID: 38791003 PMC: 11117643. DOI: 10.3390/biomedicines12051041.

References

Siegel R, Miller K, Wagle N, Jemal A . Cancer statistics, 2023. CA Cancer J Clin. 2023; 73(1):17-48. DOI: 10.3322/caac.21763. View

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

Chen S, Cao Z, Prettner K, Kuhn M, Yang J, Jiao L . Estimates and Projections of the Global Economic Cost of 29 Cancers in 204 Countries and Territories From 2020 to 2050. JAMA Oncol. 2023; 9(4):465-472. PMC: 9951101. DOI: 10.1001/jamaoncol.2022.7826. View

Carrera P, Kantarjian H, Blinder V . The financial burden and distress of patients with cancer: Understanding and stepping-up action on the financial toxicity of cancer treatment. CA Cancer J Clin. 2018; 68(2):153-165. PMC: 6652174. DOI: 10.3322/caac.21443. View

Lin L, Li Z, Yan L, Liu Y, Yang H, Li H . Global, regional, and national cancer incidence and death for 29 cancer groups in 2019 and trends analysis of the global cancer burden, 1990-2019. J Hematol Oncol. 2021; 14(1):197. PMC: 8607714. DOI: 10.1186/s13045-021-01213-z. View

Mun E, Babiker H, Weinberg U, Kirson E, Von Hoff D . Tumor-Treating Fields: A Fourth Modality in Cancer Treatment. Clin Cancer Res. 2017; 24(2):266-275. DOI: 10.1158/1078-0432.CCR-17-1117. View

Tsimberidou A, Fountzilas E, Nikanjam M, Kurzrock R . Review of precision cancer medicine: Evolution of the treatment paradigm. Cancer Treat Rev. 2020; 86:102019. PMC: 7272286. DOI: 10.1016/j.ctrv.2020.102019. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Ceccaldi R, Sarangi P, DAndrea A . The Fanconi anaemia pathway: new players and new functions. Nat Rev Mol Cell Biol. 2016; 17(6):337-49. DOI: 10.1038/nrm.2016.48. View

10.

Tsui V, Crismani W . The Fanconi Anemia Pathway and Fertility. Trends Genet. 2019; 35(3):199-214. DOI: 10.1016/j.tig.2018.12.007. View

11.

Nepal M, Che R, Zhang J, Ma C, Fei P . Fanconi Anemia Signaling and Cancer. Trends Cancer. 2017; 3(12):840-856. PMC: 5819365. DOI: 10.1016/j.trecan.2017.10.005. View

12.

Badra Fajardo N, Taraviras S, Lygerou Z . Fanconi anemia proteins and genome fragility: unraveling replication defects for cancer therapy. Trends Cancer. 2022; 8(6):467-481. DOI: 10.1016/j.trecan.2022.01.015. View

13.

Okamoto Y, Iwasaki W, Kugou K, Takahashi K, Oda A, Sato K . Replication stress induces accumulation of FANCD2 at central region of large fragile genes. Nucleic Acids Res. 2018; 46(6):2932-2944. PMC: 5888676. DOI: 10.1093/nar/gky058. View

14.

Zheng C, Ren Z, Chen H, Yuan X, Suye S, Yin H . FANCD2 promotes the malignant behavior of endometrial cancer cells and its prognostic value. Exp Cell Res. 2022; 421(2):113388. DOI: 10.1016/j.yexcr.2022.113388. View

15.

Komatsu H, Masuda T, Iguchi T, Nambara S, Sato K, Hu Q . Clinical Significance of Gene Expression and its Association with Tumor Progression in Hepatocellular Carcinoma. Anticancer Res. 2017; 37(3):1083-1090. DOI: 10.21873/anticanres.11420. View

16.

Moes-Sosnowska J, Rzepecka I, Chodzynska J, Dansonka-Mieszkowska A, Szafron L, Balabas A . Clinical importance of FANCD2, BRIP1, BRCA1, BRCA2 and FANCF expression in ovarian carcinomas. Cancer Biol Ther. 2019; 20(6):843-854. PMC: 6606037. DOI: 10.1080/15384047.2019.1579955. View

17.

Zhang X, Li L, Huang S, Liao W, Li J, Huang Z . Comprehensive Analysis of ANLN in Human Tumors: A Prognostic Biomarker Associated with Cancer Immunity. Oxid Med Cell Longev. 2022; 2022:5322929. PMC: 8947880. DOI: 10.1155/2022/5322929. View

18.

Thorsson V, Gibbs D, Brown S, Wolf D, Bortone D, Yang T . The Immune Landscape of Cancer. Immunity. 2018; 48(4):812-830.e14. PMC: 5982584. DOI: 10.1016/j.immuni.2018.03.023. View

19.

Bonneville R, Krook M, Kautto E, Miya J, Wing M, Chen H . Landscape of Microsatellite Instability Across 39 Cancer Types. JCO Precis Oncol. 2018; 2017. PMC: 5972025. DOI: 10.1200/PO.17.00073. View

20.

Zhang Y, Zhang Z . The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020; 17(8):807-821. PMC: 7395159. DOI: 10.1038/s41423-020-0488-6. View